1. Home
  2. GHRS vs CRF Comparison

GHRS vs CRF Comparison

Compare GHRS & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GHRS
  • CRF
  • Stock Information
  • Founded
  • GHRS 2018
  • CRF 1973
  • Country
  • GHRS Ireland
  • CRF United States
  • Employees
  • GHRS N/A
  • CRF N/A
  • Industry
  • GHRS Biotechnology: Pharmaceutical Preparations
  • CRF Finance/Investors Services
  • Sector
  • GHRS Health Care
  • CRF Finance
  • Exchange
  • GHRS Nasdaq
  • CRF Nasdaq
  • Market Cap
  • GHRS 849.8M
  • CRF 836.6M
  • IPO Year
  • GHRS 2021
  • CRF N/A
  • Fundamental
  • Price
  • GHRS $12.06
  • CRF $7.59
  • Analyst Decision
  • GHRS Strong Buy
  • CRF
  • Analyst Count
  • GHRS 8
  • CRF 0
  • Target Price
  • GHRS $30.63
  • CRF N/A
  • AVG Volume (30 Days)
  • GHRS 176.0K
  • CRF 1.1M
  • Earning Date
  • GHRS 05-08-2025
  • CRF 01-01-0001
  • Dividend Yield
  • GHRS N/A
  • CRF 18.10%
  • EPS Growth
  • GHRS N/A
  • CRF N/A
  • EPS
  • GHRS N/A
  • CRF 1.40
  • Revenue
  • GHRS N/A
  • CRF $11,461,786.00
  • Revenue This Year
  • GHRS N/A
  • CRF N/A
  • Revenue Next Year
  • GHRS N/A
  • CRF N/A
  • P/E Ratio
  • GHRS N/A
  • CRF $5.38
  • Revenue Growth
  • GHRS N/A
  • CRF 6.53
  • 52 Week Low
  • GHRS $6.00
  • CRF $5.70
  • 52 Week High
  • GHRS $20.50
  • CRF $9.56
  • Technical
  • Relative Strength Index (RSI)
  • GHRS 52.59
  • CRF 57.17
  • Support Level
  • GHRS $11.50
  • CRF $7.38
  • Resistance Level
  • GHRS $12.94
  • CRF $7.53
  • Average True Range (ATR)
  • GHRS 0.98
  • CRF 0.08
  • MACD
  • GHRS -0.14
  • CRF -0.03
  • Stochastic Oscillator
  • GHRS 32.73
  • CRF 50.00

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.

Share on Social Networks: